Related Experiment Videos
Aldosterone antagonists: the most underutilized class of heart failure medications
Maya Guglin1, Khaled Esmaeel Awad, Latha Polavaram
1Wayne State University, Detroit, Michigan 48201, USA. mguglin@gmail.com
Insights
Aldosterone antagonists are underutilized in severe heart failure patients despite proven benefits. This study highlights a significant disparity in prescribing patterns compared to ACE inhibitors and beta-blockers.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Aldosterone antagonists offer proven benefits in severe heart failure (HF) with systolic dysfunction.
- A potential disparity in their use compared to ACE inhibitors and beta-blockers was investigated.
Purpose of the Study:
- To determine if there is a disparity in the utilization of aldosterone antagonists versus ACE inhibitors and beta-blockers in heart failure management.
Main Methods:
- Physician questionnaires on hypothetical HF patients.
- Review of hospital charts for patients with HF exacerbation.
Main Results:
- Spironolactone use was significantly lower than ACE inhibitors and beta-blockers in both outpatient (38.2% vs 75.0% and 66.7%) and inpatient settings (58.3% vs 93.1%).
- Statistical significance (p < 0.001) confirmed the underutilization of spironolactone.
Conclusions:
- Despite strong evidence, aldosterone antagonists remain underutilized in eligible heart failure patients.
- A significant gap exists in the prescription of aldosterone antagonists compared to ACE inhibitors for patients with systolic dysfunction.
Background:
Aldosterone antagonists have been proven to be beneficial in severe heart failure (HF) as a result of systolic dysfunction. We sought to determine if there is a disparity in their utilization compared with ACE inhibitors and beta-adrenoceptor antagonists (beta-blockers).
Methods:
In the first part of the study, we asked physicians to answer a questionnaire presenting a hypothetical HF patient. In the second part, we reviewed hospital charts of patients with HF exacerbation.
Results:
Spironolactone was used less frequently than other drugs. At home, 75.0% of patients were receiving ACE inhibitors, 66.7% received beta-blockers, and 38.2% received spironolactone (p < 0.001). During the admission, 93.1% of patients received ACE inhibitors and 58.3% received spironolactone (p < 0.001).
Conclusions:
Despite good evidence, underutilization of aldosterone antagonists in patients matching the population of the RALES (Randomized Aldactone Evaluation Study) trial persists in both outpatient and inpatient settings. The difference between the usage of ACE inhibitors and spironolactone is significant in patients with systolic dysfunction equally qualifying for both medications.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:22Heart Failure Drugs: Diuretics
01:30Heart Failure V: Medical Management
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
01:22Heart Failure Drugs: β-Blockers
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers